Are beta-blockers effective or contraindicated in pulmonary arterial hypertension?

Kazufumi Nakamura, Hideki Fujio, Satoshi Akagi, Aya Miura, Toshihiro Sarashina, Nobuhiro Nishiand Hiroshi Ito

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressively elevated pulmonary vascular resistance. Sustained elevation of pulmonary vascular resistance causes severe right ventricular hypertrophy and failure. Sympathetic nerve activity is increased in patients with left ventricular failure, and treatment with beta-adrenergic receptor blockers was found to improve survival rate and cardiac function of patients with left ventricular failure. Sympathetic nerve activity is also increased in patients with PAH. Muscle sympathetic nerve activity in patients with PAH was correlated with heart rate and NYHA class. These findings indicate that treatment with adrenergic receptor blockers may be effective in patients with PAH. However, neurohormonal modulation with beta-adrenergic receptor blockers carries the risks of decreased cardiac contractility and cardiac output. The safety of treatment with beta-adrenergic receptor blockers in clinical settings has been uncertain. Meanwhile, several experimental studies have shown beneficial effects of adrenergic receptor blockers in PAH. Carvedilol inhibited the exaggerated proliferation of pulmonary artery smooth muscle cells of patients with idiopathic PAH. Treatment with carvedilol improved survival of rats with monocrotaline-induced PAH. Bisoprolol also delays progression to right heart failure in rats with PAH. Careful use of beta blockers in selected patients might be beneficial. Further studies are needed to determine whether beta-adrenergic receptor blockers are tolerable and effective in patients with PAH.

Original languageEnglish
Title of host publicationRecent Developments in Beta-Blockers Research
PublisherNova Science Publishers, Inc.
Pages101-108
Number of pages8
ISBN (Print)9781634824231, 9781634824095
Publication statusPublished - Apr 1 2015

Fingerprint

Pulmonary Hypertension
Adrenergic beta-Antagonists
Receptors, Adrenergic, beta
Adrenergic Antagonists
Vascular Resistance
Adrenergic Receptors
Bisoprolol
Monocrotaline
Right Ventricular Hypertrophy
Treatment Failure
Cardiac Output
Pulmonary Artery
Smooth Muscle Myocytes
Therapeutics
Survival Rate
Heart Failure
Heart Rate
Safety
Muscles

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Nakamura, K., Fujio, H., Akagi, S., Miura, A., Sarashina, T., & Ito, N. N. H. (2015). Are beta-blockers effective or contraindicated in pulmonary arterial hypertension? In Recent Developments in Beta-Blockers Research (pp. 101-108). Nova Science Publishers, Inc..

Are beta-blockers effective or contraindicated in pulmonary arterial hypertension? / Nakamura, Kazufumi; Fujio, Hideki; Akagi, Satoshi; Miura, Aya; Sarashina, Toshihiro; Ito, Nobuhiro Nishiand Hiroshi.

Recent Developments in Beta-Blockers Research. Nova Science Publishers, Inc., 2015. p. 101-108.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nakamura, K, Fujio, H, Akagi, S, Miura, A, Sarashina, T & Ito, NNH 2015, Are beta-blockers effective or contraindicated in pulmonary arterial hypertension? in Recent Developments in Beta-Blockers Research. Nova Science Publishers, Inc., pp. 101-108.
Nakamura K, Fujio H, Akagi S, Miura A, Sarashina T, Ito NNH. Are beta-blockers effective or contraindicated in pulmonary arterial hypertension? In Recent Developments in Beta-Blockers Research. Nova Science Publishers, Inc. 2015. p. 101-108
Nakamura, Kazufumi ; Fujio, Hideki ; Akagi, Satoshi ; Miura, Aya ; Sarashina, Toshihiro ; Ito, Nobuhiro Nishiand Hiroshi. / Are beta-blockers effective or contraindicated in pulmonary arterial hypertension?. Recent Developments in Beta-Blockers Research. Nova Science Publishers, Inc., 2015. pp. 101-108
@inbook{c379a61956634cf792e131d32de9a745,
title = "Are beta-blockers effective or contraindicated in pulmonary arterial hypertension?",
abstract = "Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressively elevated pulmonary vascular resistance. Sustained elevation of pulmonary vascular resistance causes severe right ventricular hypertrophy and failure. Sympathetic nerve activity is increased in patients with left ventricular failure, and treatment with beta-adrenergic receptor blockers was found to improve survival rate and cardiac function of patients with left ventricular failure. Sympathetic nerve activity is also increased in patients with PAH. Muscle sympathetic nerve activity in patients with PAH was correlated with heart rate and NYHA class. These findings indicate that treatment with adrenergic receptor blockers may be effective in patients with PAH. However, neurohormonal modulation with beta-adrenergic receptor blockers carries the risks of decreased cardiac contractility and cardiac output. The safety of treatment with beta-adrenergic receptor blockers in clinical settings has been uncertain. Meanwhile, several experimental studies have shown beneficial effects of adrenergic receptor blockers in PAH. Carvedilol inhibited the exaggerated proliferation of pulmonary artery smooth muscle cells of patients with idiopathic PAH. Treatment with carvedilol improved survival of rats with monocrotaline-induced PAH. Bisoprolol also delays progression to right heart failure in rats with PAH. Careful use of beta blockers in selected patients might be beneficial. Further studies are needed to determine whether beta-adrenergic receptor blockers are tolerable and effective in patients with PAH.",
author = "Kazufumi Nakamura and Hideki Fujio and Satoshi Akagi and Aya Miura and Toshihiro Sarashina and Ito, {Nobuhiro Nishiand Hiroshi}",
year = "2015",
month = "4",
day = "1",
language = "English",
isbn = "9781634824231",
pages = "101--108",
booktitle = "Recent Developments in Beta-Blockers Research",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Are beta-blockers effective or contraindicated in pulmonary arterial hypertension?

AU - Nakamura, Kazufumi

AU - Fujio, Hideki

AU - Akagi, Satoshi

AU - Miura, Aya

AU - Sarashina, Toshihiro

AU - Ito, Nobuhiro Nishiand Hiroshi

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressively elevated pulmonary vascular resistance. Sustained elevation of pulmonary vascular resistance causes severe right ventricular hypertrophy and failure. Sympathetic nerve activity is increased in patients with left ventricular failure, and treatment with beta-adrenergic receptor blockers was found to improve survival rate and cardiac function of patients with left ventricular failure. Sympathetic nerve activity is also increased in patients with PAH. Muscle sympathetic nerve activity in patients with PAH was correlated with heart rate and NYHA class. These findings indicate that treatment with adrenergic receptor blockers may be effective in patients with PAH. However, neurohormonal modulation with beta-adrenergic receptor blockers carries the risks of decreased cardiac contractility and cardiac output. The safety of treatment with beta-adrenergic receptor blockers in clinical settings has been uncertain. Meanwhile, several experimental studies have shown beneficial effects of adrenergic receptor blockers in PAH. Carvedilol inhibited the exaggerated proliferation of pulmonary artery smooth muscle cells of patients with idiopathic PAH. Treatment with carvedilol improved survival of rats with monocrotaline-induced PAH. Bisoprolol also delays progression to right heart failure in rats with PAH. Careful use of beta blockers in selected patients might be beneficial. Further studies are needed to determine whether beta-adrenergic receptor blockers are tolerable and effective in patients with PAH.

AB - Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by progressively elevated pulmonary vascular resistance. Sustained elevation of pulmonary vascular resistance causes severe right ventricular hypertrophy and failure. Sympathetic nerve activity is increased in patients with left ventricular failure, and treatment with beta-adrenergic receptor blockers was found to improve survival rate and cardiac function of patients with left ventricular failure. Sympathetic nerve activity is also increased in patients with PAH. Muscle sympathetic nerve activity in patients with PAH was correlated with heart rate and NYHA class. These findings indicate that treatment with adrenergic receptor blockers may be effective in patients with PAH. However, neurohormonal modulation with beta-adrenergic receptor blockers carries the risks of decreased cardiac contractility and cardiac output. The safety of treatment with beta-adrenergic receptor blockers in clinical settings has been uncertain. Meanwhile, several experimental studies have shown beneficial effects of adrenergic receptor blockers in PAH. Carvedilol inhibited the exaggerated proliferation of pulmonary artery smooth muscle cells of patients with idiopathic PAH. Treatment with carvedilol improved survival of rats with monocrotaline-induced PAH. Bisoprolol also delays progression to right heart failure in rats with PAH. Careful use of beta blockers in selected patients might be beneficial. Further studies are needed to determine whether beta-adrenergic receptor blockers are tolerable and effective in patients with PAH.

UR - http://www.scopus.com/inward/record.url?scp=84956835593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956835593&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84956835593

SN - 9781634824231

SN - 9781634824095

SP - 101

EP - 108

BT - Recent Developments in Beta-Blockers Research

PB - Nova Science Publishers, Inc.

ER -